Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis.

× No keyword cloud information.

9 in total

Review 1. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors: Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal: Adv Drug Deliv Rev Date: 2017-04-25 Impact factor: 15.470

2. Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.

Authors: Sofia Jönsson; Henrik Hjorth-Hansen; Bob Olsson; Hans Wadenvik; Anders Sundan; Therese Standal
Journal: J Bone Miner Metab Date: 2011-10-14 Impact factor: 2.626

3. Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.

Authors: Hongwei Cheng; Paul W Clarkson; Dongxia Gao; Marina Pacheco; Yuzhuo Wang; Torsten O Nielsen
Journal: Sarcoma Date: 2010-10-13

Review 4. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.

Authors: Mehdi Brahmi; Armelle Vinceneux; Philippe A Cassier
Journal: Curr Treat Options Oncol Date: 2016-02

5. The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines.

Authors: Andrea Morandi; Valentina Barbetti; Maria Riverso; Persio Dello Sbarba; Elisabetta Rovida
Journal: PLoS One Date: 2011-11-09 Impact factor: 3.240

Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis.

Review 1. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

2. Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.

3. Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.

Review 4. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.

5. The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines.

6. Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.

7. Tenosynovial giant cell tumor of the cervical spine: a case report.

Review 8. Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.

9. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib.